Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: Webinars

Webinar presented by Integral Molecular and Fierce Biotech – Redefining Antibody Specificity Profiling for IND

Thursday, June 6, 2024
8 am PT, 11 am ET, 17:00 CET

Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods, such as tissue cross-reactivity studies, are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. So, what are the alternatives?

Join our webinar to learn about the new, innovative cell-based protein array approach to specificity profiling. We’ll take a deep dive into the Membrane Proteome Array (MPA), a 6,000-protein array platform that tests binding of biotherapeutics across the full human membrane proteome expressed in unfixed cells.

Attendees will learn how:

  • Integral Molecular’s MPA is used to rapidly and accurately identify potential off-target binding liabilities
  • MPA data support both lead selection and IND submissions with advantages over tissue cross-reactivity studies
  • Cell protein arrays, like the MPA, are rapidly progressing towards FDA endorsement through inclusion in CAR-T development guidelines and qualification as an antibody Drug Development Tool
 Integral Molecular and Fierce webinar 2024

Register now

Webinar presented by Integral Molecular and The Antibody Society – Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

Thursday, April 25, 2024
8 am PT, 11 am ET, 17:00 CET
View the recording

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development.

In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success

Antibody Society and Integral Molecular webinar

View the recording

Webinar presented by Integral Molecular and Fierce Biotech – Innovative Research Tools to Combat Biological Threats

Thursday, October 12, 2023
8 am PT, 11 am ET, 17:00 CET
View the recording

A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks?

Join leaders in industry and academia for this important, one-hour discussion on the latest technologies, experiences, and strategies within the study and development of therapeutics against emerging viruses, such as influenza, SARS-CoV-2, and dengue. We’ll explore:

  • The use of pseudovirus Reporter Virus Particles (RVPs) in place of live viruses
  • How to drive the safe study of new virus variants and mutations of interest
  • Why innovative research tools play a critical role in the development of vaccines and treatments for a range of biological threats
  • Real-world case studies from top industry organizations
  • And more


Fierce and Integral Molecular Webinar- Mobilizing Safe Research Tools for Pandemic Preparedness. Headshots of webinar speakers: Kyle Doolan, Ph.D. of Integral Molecular, Chun-Nan Chen, Ph.D. of Single Cell Technology, Inc. and James E. Crowe, Jr., M.D. of Vanderbilt University Medical Center.

View the recording

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023
8 am PT, 11 am ET, 17:00 CET
Watch the webinar

Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many targets have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. In this webinar, industry experts will share innovative strategies they have used to unlock challenging targets including membrane proteins.

They will discuss:

  • Key questions that scientists should ask before embarking on an antibody discovery campaign
  • How to leverage advancements in immunization—including RNA—to target native epitopes and generate diverse antibodies
  • Strategies for unlocking conserved antibody targets using approaches such as divergent host species
  • Case studies of two challenging targets, claudin 6 and GPRC5D, with a focus on key innovations that led to the discovery of preclinical candidates including CTIM-76, a pre-IND (Investigational New Drug) stage molecule being developed for oncology therapeutics


Fierce Life Sciences and Integral Molecular webinar speakers banner

Watch the webinar

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array


Thursday, June 22, 2023
Watch the webinar

Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding; however, their predictive value for in vivo safety and toxicity is poor. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk antibody-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.

In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions, resulting in successful IND filings for CAR-T cell therapies where conventional approaches did not suffice. We will also describe the newest additions to this 6,000-protein cell array and the status of its consideration by the FDA as a qualified Drug Development Tool.

With a focus on specificity screening, this webinar assembles experts in antibody discovery and development and features presentations from Integral Molecular, Cabaletta Bio, and The University of Pennsylvania.

  • Understand how Integral Molecular’s MPA is used to identify potential off-target binding liabilities
  • Learn how MPA data supports IND submissions with advantages over traditional tissue cross-reactivity studies
  • Discover how the MPA was used to rapidly evaluate the specificity of novel CAR-T cell therapies for autoimmunity and cancer


GEN and Integral Molecular Webinar- Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array. Headshots of webinar speakers: Rachel Fong of Integral Molecular, Darshil Patel of Cabaletta Bio and Donald Siegel of University of Pennsylvania.